Ropivacaine Pharmacokinetics After Erector Spinae Block

• Status: Not yet recruiting
• Trial end date: 2024-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary aim is to evaluate the analgesic efficacy of either technique by measuring cumulative morphine consumption in the first 24 hours after an erector spinae plane block with 2 ml/kg of ropivacaine 0.1% (2 ml/kg) or 1 ml/kg of ropivacaine 0.2%.

The secondary aim of this study is to describe the pharmacokinetics of ropivacaine 0.1% and ropivacaine 0.2% after erector spinae block in children undergoing posterior spinal fusion.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
• Treatments: Ropivacaine

Criteria

Inclusion Criteria:

• Patients ≥ 8 year older and > 25 kg undergoing posterior spinal fusion surgery

• Parents or legal guardians that are fluent in French of English

Exclusion Criteria:

• Patients with any contraindication to locoregional anesthesia

• Patients that are expected to be intubation for a prolonged period of time after surgery

• Patients with anemia (hematocrit < 30%) before surgery or at time of the first study blood draw

• Patients that do not receive an erector spinae plane block

• Parents or legal Patient/legal guardian that to not consent to participate in the study